A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer

Neuroendocrine/small-cell prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer, which typically develops after prolonged treatment for metastatic castration-resistant disease, but can, less commonly, occur de novo. We describe a case of de novo NEPC in a tumor with mixed pathol...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncological medicine 2024, Vol.2024 (1), p.7998149
Main Authors: Dalal, Aryan, Clark-Garvey, Sean, Gdowski, Andrew, Zhang, Sophia, Wobker, Sara E, Rowe, Steven P, Altun, Ersan, Beltran, Himisha, Milowsky, Matthew I
Format: Article
Language:English
Subjects:
Abdomen
Androgens
Antigens
Back pain
Biopsy
Cancer
Cancer therapies
Care and treatment
Case Report
Chemotherapy
Development and progression
DNA methylation
Fractures
Gastrointestinal diseases
Histology
Hypertension
Intestinal obstruction
Liver
Liver cancer
Metastasis
Patients
Pelvis
Prostate cancer
Tomography
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroendocrine/small-cell prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer, which typically develops after prolonged treatment for metastatic castration-resistant disease, but can, less commonly, occur de novo. We describe a case of de novo NEPC in a tumor with mixed pathology including acinar adenocarcinoma and neuroendocrine/small-cell carcinoma with rapid progression of metastatic disease. Despite initiation of treatment with androgen deprivation therapy (ADT) and chemotherapy, the patient continued to exhibit progression leading to multiple complications including a large bowel obstruction and ultimately progressive hepatic metastases resulting in liver failure. This case illustrates the clinical presentation and highly aggressive nature of de novo NEPC. Recognizing atypical clinical progression in prostate cancer is critical for the detection of NEPC; however, despite early identification and initiation of treatment, the prognosis remains poor, thus highlighting the need for further study into NEPC biology and novel therapeutic approaches.
ISSN:2090-6706
2090-6714
DOI:10.1155/2024/7998149